肝癌类器官的药学-蛋白质组学特征分析助力精准肿瘤学
研究建立了患者来源肝癌类器官生物库(LICOB),通过多组学(基因组、表观基因组、转录组、蛋白质组)分析全面反映多种肝癌类型的组织学和分子特征。蛋白质组学分析识别出与患者预后相关的增殖型和代谢型类器官亚型,高通量药物筛选揭示了各亚型与特定多组学特征相关的不同反应模式。整合药学-蛋白质组学数据识别了与药物反应相关的分子特征并预测了个性化治疗的潜在药物组合,mTOR抑制剂替西罗莫司与多靶点酪氨酸激酶抑制剂仑伐替尼的协同抑制效应在类器官和患者来源异种移植模型中得到了验证。
要点
- LICOB生物库通过多组学分析全面反映多种肝癌类型的组织学和分子特征。
- 识别出与患者预后相关的增殖型和代谢型类器官亚型,各亚型药物反应模式与特定多组学特征相关。
- 替西罗莫司与仑伐替尼的协同抑制效应在类器官和患者来源异种移植模型中得到验证。
核心结论
- 本研究为肝癌生物学和药理学依赖性研究提供了丰富资源,可能有助于实现功能性精准医学。
研究设计与样本
- 建立患者来源肝癌类器官生物库(LICOB),通过基因组、表观基因组、转录组和蛋白质组多组学分析进行全面表征。
主要发现
- 蛋白质组学分析识别出与患者预后相关的增殖型和代谢型类器官亚型。
- 高通量药物筛选揭示各亚型与特定多组学特征相关的不同反应模式。
- 整合药学-蛋白质组学数据识别了与药物反应相关的分子特征并预测了个性化治疗的潜在药物组合。
- mTOR抑制剂替西罗莫司与多靶点酪氨酸激酶抑制剂仑伐替尼的协同抑制效应在类器官和患者来源异种移植模型中得到验证。
- 提供了用户友好的网络门户以服务生物医学研究社区。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Organoid models have the potential to recapitulate the biological and pharmacotypic features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis for drug response features and biomarker investigation for precision therapy of patients with liver cancer are still lacking. We established a patient-derived liver cancer organoid biobank (LICOB) that comprehensively represents the histological and molecular characteristics of various liver cancer types as determined by multiomics profiling, including genomic, epigenomic, transcriptomic, and proteomic analysis. Proteogenomic profiling of LICOB identified proliferative and metabolic organoid subtypes linked to patient prognosis. High-throughput drug screening revealed distinct response patterns of each subtype that were associated with specific multiomics signatures. Through integrative analyses of LICOB pharmaco-proteogenomics data, we identified the molecular features associated with drug responses and predicted potential drug combinations for personalized patient treatment. The synergistic inhibition effect of mTOR inhibitor temsirolimus and the multitargeted tyrosine kinase inhibitor lenvatinib was validated in organoids and patient-derived xenografts models. We also provide a user-friendly web portal to help serve the biomedical research community. Our study is a rich resource for investigation of liver cancer biology and pharmacological dependencies and may help enable functional precision medicine.
引用
- Ji S, Feng L, Fu Z, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci Transl Med. 2023. PMID: 37494474. doi:10.1126/scitranslmed.adg3358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。